These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38996870)

  • 1. Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.
    Cabello M; Hernández-García M; Maruri-Aransolo A; Michelena M; Pérez-Viso B; Ponce-Alonso M; Cantón R; Ruiz-Garbajosa P
    J Glob Antimicrob Resist; 2024 Sep; 38():281-291. PubMed ID: 38996870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early OXA-48-Producing
    Gijón D; Tedim AP; Valverde A; Rodríguez I; Morosini MI; Coque TM; Manrique M; Pareja E; Tobes R; Ruiz-Garbajosa P; Cantón R
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32269151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
    Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
    Öztaş S; Er DK; Dündar D; Keçeli SA
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):110-120. PubMed ID: 38837219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-Relebactam Susceptibility in
    Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
    Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and Characteristics of Carbapenemase-Producing Enterobacteriaceae in Three Tertiary-Care Korean University Hospitals between 2017 and 2018.
    Kim SH; Kim GR; Jeong J; Kim S; Shin JH
    Jpn J Infect Dis; 2020 Nov; 73(6):431-436. PubMed ID: 32475870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
    Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.
    Chew KL; Tay MKL; Cheng B; Lin RTP; Octavia S; Teo JWP
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760136
    [No Abstract]   [Full Text] [Related]  

  • 11. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM; Antochevis LC; Magagnin CM; Arns B; Vieceli T; Pereira DC; Lutz L; de Souza ÂC; Dos Santos JN; Guerra RR; Medeiros GS; Santoro L; Falci DR; Rigatto MH; Barth AL; Martins AF; Zavascki AP
    J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic and molecular characterization of multidrug-resistant Enterobacterales isolated from clinical samples in Palestine: a focus on extended-spectrum β-lactamase- and carbapenemase-producing isolates.
    Ibaideya MA; Taha AA; Qadi M
    BMC Infect Dis; 2024 Aug; 24(1):812. PubMed ID: 39134953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the Klebsiella pneumoniae carbapenemase type 2 Carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid.
    Rasheed JK; Biddle JW; Anderson KF; Washer L; Chenoweth C; Perrin J; Newton DW; Patel JB
    J Clin Microbiol; 2008 Jun; 46(6):2066-9. PubMed ID: 18385437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARGONAUT-III and -V: susceptibility of carbapenem-resistant
    Jacobs MR; Abdelhamed AM; Good CE; Mack AR; Bethel CR; Marshall S; Hujer AM; Hujer KM; Patel R; van Duin D; Fowler VG; Rhoads DD; Six DA; Moeck G; Uehara T; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0075124. PubMed ID: 39133021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
    Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Al Thawra University Hospital, Sana'a, Yemen.
    Alsharapy SA; Gharout-Sait A; Muggeo A; Guillard T; Cholley P; Brasme L; Bertrand X; Moghram GS; Touati A; De Champs C
    Microb Drug Resist; 2020 Mar; 26(3):211-217. PubMed ID: 31397629
    [No Abstract]   [Full Text] [Related]  

  • 20. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.